Hybridon preclinical data

HYBN researchers and colleagues published preclinical data in the Proceedings of the National Academy of Sciences showing that two antisense compounds targeting vascular endothelial growth factor (VEGF) can inhibit retinal neovascularization, a major cause of visual loss and blindness.

In mice, intravitreal injections of two different compounds (Vm and M3), prior to the onset of proliferative retinopathy, reduced new blood vessel growth by a mean of 25 percent and 31 percent, respectively, compared to control groups injected with sense oligos. This inhibition resulted in a 40-66 percent reduction in the level of VEGF protein. ...